News
PBLA
0.2703
-24.71%
-0.0887
Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For ASPIRE Trial Studying Ivospemin In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of
Benzinga · 1d ago
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers
Benzinga · 3d ago
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Benzinga · 4d ago
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day extension to March 13, 2023 to regain compliance.
Benzinga · 09/23 16:16
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket
Gainers HHG Capital Corporation (NASDAQ: HHGC) shares rose 42.1% to $14.56 in pre-market trading.
Benzinga · 09/23 11:16
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers
Benzinga · 09/23 07:42
Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.
Benzinga · 09/20 07:16
Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.
Benzinga · 09/19 16:29
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday.
Benzinga · 09/19 10:53
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.
Benzinga · 09/19 05:53
Panbela Therapeutics Inc Files For Public Offering Of 28.9M Shares Of Common Stock And Common Stock Purchase Warrants
-Reuters
Benzinga · 09/06 10:10
Panbela Therapeutics Says On Aug 19, Co Received A Letter From NASDAQ Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
-SEC Filing
Benzinga · 08/25 12:11
Panbela Therapeutics GAAP EPS of -$1.51
Panbela Therapeutics press release (<span class="ticker-hover-wrapp...
Seekingalpha · 08/15 20:28
BRIEF-Panbela Reports Q2 2022 Financial Results
BRIEF-Panbela Reports Q2 2022 Financial Results
Reuters · 08/15 20:11
Earnings Scheduled For August 15, 2022
  Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter.
Benzinga · 08/15 09:30
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Expects interim data by early 2024MINNEAPOLIS, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today ann...
GlobeNewswire · 08/11 13:00
Panbela Therapeutics Says it Has Australian Clearance to Expand Trial of SBP-101 to Treat Pancreatic Cancer
Panbela Therapeutics Says it Has Australian Clearance to Expand Trial of SBP-101 to Treat Pancreatic Cancer
MT Newswires · 08/04 13:44
Panbela Expands Aspire Trial To Australia, Studying SBP-101 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has received approval from the
Benzinga · 08/04 13:07
Panbela Expands Aspire Trial to Australia, Studying SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
MINNEAPOLIS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has received approval fr...
GlobeNewswire · 08/04 13:00
Panbela Schedules Conference Call on, August 15, 2022, to Report 2022 Second Quarter Financial Results
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a confere...
GlobeNewswire · 08/01 20:00
More
Webull provides a variety of real-time PBLA stock news. You can receive the latest news about Panbela Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About PBLA
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The Company is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.